Published in Women's Health Weekly, April 6th, 2006
"Prediction of outcome in patients with metastatic breast cancer remains problematical. The present study evaluated the value of an inflammation-based prognostic score (Glasgow Prognostic Score, GPS) in patients with metastatic breast cancer," scientists writing in the British Journal of Cancer reported.
"The GPS was constructed as follows: patients with both an elevated C-reactive protein (410 mg/L) and hypoalbuminaemia (<35 g/L) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly